Insulet (NASDAQ:PODD) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, January 18th.

PODD has been the subject of a number of other reports. Jefferies Group lifted their price target on shares of Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Wedbush reiterated a “buy” rating and set a $65.00 price target (up from $60.00) on shares of Insulet in a research report on Tuesday, October 10th. Zacks Investment Research cut shares of Insulet from a “buy” rating to a “hold” rating in a research report on Saturday, November 11th. Barclays reiterated a “buy” rating and set a $78.00 price target on shares of Insulet in a research report on Wednesday, December 13th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $50.00 price target on shares of Insulet in a research report on Wednesday, September 27th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. Insulet currently has an average rating of “Buy” and an average target price of $62.53.

Shares of Insulet (NASDAQ:PODD) traded up $0.02 on Thursday, hitting $78.08. 122,017 shares of the company’s stock were exchanged, compared to its average volume of 560,357. Insulet has a 1-year low of $38.43 and a 1-year high of $78.65. The firm has a market capitalization of $4,524.68, a PE ratio of -156.16 and a beta of 1.58. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The business had revenue of $121.80 million during the quarter, compared to analysts’ expectations of $114.02 million. During the same period last year, the business earned ($0.05) earnings per share. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. equities analysts forecast that Insulet will post -0.43 earnings per share for the current year.

In other Insulet news, Director James C. Mullen acquired 2,500 shares of the stock in a transaction dated Monday, November 13th. The stock was acquired at an average price of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.60% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Insulet by 0.5% in the second quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock valued at $445,755,000 after purchasing an additional 39,836 shares during the period. Capital Research Global Investors boosted its stake in shares of Insulet by 2.5% in the second quarter. Capital Research Global Investors now owns 5,883,633 shares of the medical instruments supplier’s stock valued at $301,889,000 after purchasing an additional 145,724 shares during the period. Vanguard Group Inc. lifted its stake in Insulet by 2.2% in the second quarter. Vanguard Group Inc. now owns 4,655,119 shares of the medical instruments supplier’s stock worth $238,854,000 after acquiring an additional 98,272 shares during the last quarter. Frontier Capital Management Co. LLC lifted its stake in Insulet by 42.4% in the fourth quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock worth $144,633,000 after acquiring an additional 624,465 shares during the last quarter. Finally, Fred Alger Management Inc. lifted its stake in Insulet by 4.2% in the second quarter. Fred Alger Management Inc. now owns 1,264,025 shares of the medical instruments supplier’s stock worth $64,857,000 after acquiring an additional 50,780 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “BidaskClub Lowers Insulet (PODD) to Sell” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/01/20/bidaskclub-downgrades-insulet-podd-to-sell.html.

Insulet Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the Omnipod Insulin Management System (the Omnipod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.